Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma

Regression of Multiple Melanocytic Nevi in Two Patients on Nivolumab for Metastatic Melanoma

“…Lightening without halo is a known phenomenon, especially in patients treated with pembrolizumab [ 4 , 5 ]. There are few reports regarding regression of melanocytic nevi in patients treated with nivolumab: one similar to our patient, with no inflammation or halo, and another patient who experimented inflammation before regression, with no halo [ 6 , 7 ]. Though some articles suggest that regression of melanocytic nevi may be related to the therapeutic effect of the anti-PD1 drug and could be interpreted as a sign of good therapeutical response, our patients both experimented progression despite nivolumab treatment; therefore, more studies are required to shed light on this matter [ 2 , 5 , 7 ].…”